Cassava Sciences to Present at the Jefferies Biotech CNS/Neuro Summit in NY
05 oct. 2023 09h15 HE
|
Cassava Sciences, Inc.
AUSTIN, Texas, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company committed to the treatment of Alzheimer’s disease dementia, today announced that Remi...
Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer’s Disease
02 oct. 2023 09h00 HE
|
Cassava Sciences, Inc.
804 Alzheimer’s Patients Are Enrolled in a Pivotal Phase 3 Clinical TrialA Second Pivotal Phase 3 Clinical Trial Is Expected to Complete Enrollment Q4 2023, With a Target Enrollment of Approximately...
Cassava Sciences Announces Positive Interim Safety Review of Simufilam On-going Phase 3 Trials in Patients with Alzheimer’s Disease
18 sept. 2023 09h15 HE
|
Cassava Sciences, Inc.
An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Simufilam in On-Going Phase 3 Clinical Trials.The DSMB Recommended the Phase 3 Trials...
Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer’s Disease
13 sept. 2023 17h20 HE
|
Cassava Sciences, Inc.
New cell biology data from Europe shows simufilam interrupts a pathogenic signaling pathway in Alzheimer’s disease.Results corroborate prior research from other academic researchers.These data once...
Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer’s Disease
11 sept. 2023 09h10 HE
|
Cassava Sciences, Inc.
New cell biology data from Europe shows simufilam interrupts a pathogenic signaling pathway in Alzheimer’s disease.Results corroborate prior research from other academic researchers.These data once...
Cassava Sciences Invited to Present in Four Upcoming Investor Conferences
06 sept. 2023 09h15 HE
|
Cassava Sciences, Inc.
AUSTIN, Texas, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company committed to the treatment of Alzheimer’s disease dementia, today announced that it...
Cassava Sciences Reports Q2 2023 Financial Results and Operating Updates
03 août 2023 09h07 HE
|
Cassava Sciences, Inc.
Results of a randomized, controlled trial of oral simufilam in Alzheimer’s disease announced July 2023.Over 1,587 patients now enrolled in Phase 3 studies of simufilam in Alzheimer’s disease, an...
Oral Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer’s Disease
05 juil. 2023 09h15 HE
|
Cassava Sciences, Inc.
Simufilam Slowed Cognitive Decline by 38% Versus Placebo Over 6 months in Patients with Mild-to-Moderate Alzheimer’s Disease.Drug Effects Favored Mild Alzheimer’s Disease.In Mild Alzheimer’s,...
New Research Shows Simufilam Suppresses Overactive mTOR
27 juin 2023 09h15 HE
|
Cassava Sciences, Inc.
Overactive mTOR Plays a Key Role in Aging and Alzheimer’s Disease.Simufilam Suppresses Overactive mTOR, Suggesting a Beneficial Drug Effect.Research is Published in Frontiers in Aging, a Peer-reviewed...
New Publication Highlights Basic Science Supporting Simufilam
12 juin 2023 09h15 HE
|
Cassava Sciences, Inc.
Publication Reviews Certain Receptor-Protein Interactions. Provides Overview of Basic Science Supporting Simufilam. Published in Drug Development Research, a Peer-Reviewed Journal. AUSTIN, Texas,...